Our lab is broadly interested in understanding cancer development driven by genetic mutations in patients. How does the cell division and chromosome segregation altered by oncogenic signaling pathway? How to target cancer aneuploidy and chromosome instability (CIN)? We employ multidisciplinary approaches to tackle these fundamental questions central to cell biology and human health. We have a particular interest in targeting three most frequently altered signaling pathway in human cancers, such as PI3K/AKT/PTEN/MTOR pathway, RAS/RAF signaling pathway, and TGF-beta pathway. Our disease focus is solid tumors with a particular emphasis on breast cancer and prostate cancer. We are also actively engaged in translating basic mechanistic insights to the development of novel therapeutics.
